Nkarta receives u.s. fda orphan drug designation for nkx101 for treatment of patients with aml

South san francisco, calif., dec. 16, 2021 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a clinical-stage biopharmaceutical company developing engineered natural killer (nk) cell therapies to treat cancer, today announced that the u.s. food and drug administration (fda) has granted orphan drug designation (odd) to nkx101 for treatment of acute myeloid leukemia (aml).
NKTX Ratings Summary
NKTX Quant Ranking